Two Blokes

Ultragenyx shares plunge after bone disorder trial misses key interim goal

  • click to rate
    Posted by Two Blokes Jul 10 - Filed in Stock - 10 views
    Shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) slumped around 26% on Thursday afternoon after the company and partner Mereo BioPharma said their late-stage study of setrusumab in osteogenesis imperfecta failed to meet a key interim goal. Ultragenyx is developing setrusumab as a potential first-in-class treatment for osteogenesis imperfecta, a rare genetic bone disorder with no approved therapies in the US.